RBC Capital Markets has softened its outlook on drugmaker Merck, trimming its price target to $145 while keeping a “sector perform” rating. The move comes just ahead of Merck’s third-quarter earnings report on October 29 and the release of new melanoma data at the ESMO cancer conference.
The bank’s reasoning centers on Merck’s own guidance: the company is signaling only “modest” growth in 2027 while also planning heavier spending, including higher day-to-day operating costs. When costs rise faster than sales, profit margins can get squeezed, and analysts typically respond by trimming future profit and cash-flow forecasts in their valuation models.
What RBC expects for the quarter
For the upcoming third-quarter report, RBC expects adjusted earnings per share of $2.12, essentially in line with the FactSet consensus estimate of $2.11. That suggests the market is already pricing in a fairly steady quarter, with no major surprises expected on the bottom line.
On the revenue side, RBC notes that Keytruda, Merck’s blockbuster cancer drug, is still growing in the U.S. but at a more moderate pace as it approaches saturation in its core cancer types. Keytruda has been the company’s growth engine for years, but with many of its main indications now well penetrated, the days of double-digit percentage growth are likely behind it.
Meanwhile, the Gardasil vaccine, which protects against HPV-related cancers, should get a boost from the usual back-to-school seasonal bump. That pattern is well established, as many adolescents receive the vaccine before the school year starts.
The bigger swing factor: ESMO data
Beyond the quarter, the most important catalyst is clinical data. Merck is due to present results from a melanoma study at ESMO, the European Society for Medical Oncology’s annual meeting. A positive readout could reassure investors that Merck has a growth runway beyond 2027, while a disappointing result could raise fresh doubts about the company’s pipeline.
Melanoma is a key area for Merck, and the data could influence how analysts and investors view the company’s long-term prospects. If the study shows a meaningful benefit, it could open up new uses for Keytruda or other drugs in Merck’s portfolio. If not, the company may have to rely more heavily on cost-cutting or other measures to support earnings.
What it means for investors
For everyday investors, the key takeaway is the concept of operating leverage. When a company can grow revenue without adding much cost, profits can rise faster than sales. But when a company has to spend more just to keep growth steady, margins can shrink, and analysts tend to lower their profit estimates.
RBC’s new price target of $145 is roughly where Merck’s stock is already trading. That means the target itself isn’t the main story — it’s what could change the narrative. The October 29 earnings report and the ESMO melanoma data are the two events that could reset expectations for Merck’s post-2027 growth and profitability.
If Merck beats earnings or delivers strong melanoma data, the stock could move higher even with a modest target. Conversely, a miss or a weak readout could push the stock below the target. Investors should watch these catalysts closely, but remember that a single analyst’s price target is just one opinion.
For context, other drugmakers are facing similar questions about growth. For example, Novartis is expected to lift its growth target at its capital markets day, while UBS sees Haleon trimming its FY26 growth target to around 3%. These moves highlight the broader pressure on pharma and consumer health companies to sustain growth in a competitive environment.
Merck’s situation is also a reminder that even large, established companies face growth limits. Keytruda’s maturation is a natural part of the drug lifecycle, and investors will need to weigh the company’s pipeline and cost discipline against its slowing core growth.
As always, this is not a recommendation to buy or sell Merck. Instead, it’s a look at what analysts are watching and how the upcoming events could shape the stock’s direction. For those holding Merck, the next few weeks could be pivotal.
